Search clinical trials for: 4SC

Total 43 results

Shenzhen Geno-Immune Medical Institute
The Second Affiliated Hospital of Hainan Medical University; Beijing Jingdu...

Recruiting

4SCAR19U T Cells Targeting B Cell Malignancies

B Cell Malignancies

China
Shenzhen Geno-Immune Medical Institute
The Second Affiliated Hospital of Hainan Medical University; Beijing Jingdu...

Recruiting

Universal 4SCAR7U Targeting CD7-positive Malignancies

Acute Myeloid Leukemia | T-cell Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic Lymphoma | NK Cell Lymphoma

China
Shenzhen Geno-Immune Medical Institute
Guilin Hospital of Chinese Traditional and Western Medicine

Recruiting

CAR-T Cells Targeting Autoimmune Diseases

Autoimmune Diseases

China
Shenzhen Geno-Immune Medical Institute

Recruiting

GD2/CD70 Bi-specific CAR-T Cell Therapy

Cancer Disease

China
Shenzhen Geno-Immune Medical Institute

Recruiting

GD2/PSMA Bi-specific CAR-T Cell Therapy

Solid Tumor

China
Shenzhen Geno-Immune Medical Institute

Recruiting

GD2/CD56 Bi-specific CAR-T Cell Therapy

Malignant Disease

China
Shenzhen Geno-Immune Medical Institute

Recruiting

PSMA/CD70 Bi-specific CAR-T Cell Therapy

Cancer Disease

China
Shenzhen Geno-Immune Medical Institute

Recruiting

CD19/79b Bi-specific CAR-T Cell Therapy

B Cell Malignancies

China
Shenzhen Geno-Immune Medical Institute

Recruiting

CD19/70 Bi-specific CAR-T Cell Therapy

B Cell Malignancies

China
Shenzhen Geno-Immune Medical Institute

Recruiting

CD19/22 Bi-specific CAR-T Cell Therapy

B Cell Malignancies

China
Shenzhen Geno-Immune Medical Institute
Shenzhen Children's Hospital

Recruiting

4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma

Neuroblastoma

China
Shenzhen Geno-Immune Medical Institute
Sun Yat-sen University; Shenzhen Children's Hospital

Recruiting

Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276

Solid Tumor

China
Shenzhen Geno-Immune Medical Institute
The Seventh Affiliated Hospital of Sun Yat-sen University

Recruiting

Multi-4SCAR-T Therapy Targeting Breast Cancer

Breast Cancer

China
Shenzhen Geno-Immune Medical Institute
The Seventh Affiliated Hospital of Sun Yat-sen University; Shenzhen Children...

Recruiting

Multi-CAR-T Cells Targeting B Cell Lymphomas

B Cell Lymphoma (BCL)

China
Shenzhen Geno-Immune Medical Institute
The Seventh Affiliated Hospital of Sun Yat-sen University; Shenzhen Children... and other collaborators

Recruiting

PSMA-specific CAR-T Cell Therapy

PSMA Positive Tumors or Tumor Tissues

China
Shenzhen Geno-Immune Medical Institute
The Seventh Affiliated Hospital of Sun Yat-sen University; Shenzhen Children... and other collaborators

Recruiting

4SCAR-T Therapy Post CD19-targeted Immunotherapy

CD19 Negative B-cell Malignancies

China
Shenzhen Geno-Immune Medical Institute
The Seventh Affiliated Hospital of Sun Yat-sen University; Shenzhen Children... and other collaborators

Recruiting

4SCAR-CD44v6 T Cell Therapy Targeting Cancer

Cancers Which Are CD44v6 Positive

China
Shenzhen Geno-Immune Medical Institute

Recruiting

CAR-T Immunotherapy Targeting CD19- ALL

B-cell Leukemia

China
4SC AG

Completed

Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1 (MERKLIN2)

Merkel Cell Carcinoma

Spain, Netherlands, Belgium, Germany, France, Italy
Zhujiang Hospital
Shenzhen Geno-Immune Medical Institute

Withdrawn

Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies

B-Cell Leukemia | B-Cell Lymphoma

China
Zhujiang Hospital

Completed

Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma (4SCAR-GD2)

Effects of Immunotherapy | Neuroblastoma

China
The Netherlands Cancer Institute
4SC

Active, not recruiting

Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma (DONIMI)

Malignant Melanoma Stage III

Netherlands
The Netherlands Cancer Institute
4SC AG

Active, not recruiting

Pre-operative Immunotherapy in Stage II-III Urothelial Cancer (TURANDOT)

Urothelial Carcinoma

Netherlands
4SC AG

Active, not recruiting

Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) (RESMAIN)

Lymphoma, T-Cell, Cutaneous | Mycosis Fungoides | Sezary Syndrome

Austria, Spain, Germany, United Kingdom, France, Belgium, Japan, Switzerland, Italy, Poland, Netherlands, Greece
4SC AG

Completed

A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat

Mycosis Fungoides | Sezary Syndrome | Cutaneous T Cell Lymphoma

United Kingdom
4SC AG

Completed

4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy (SENSITIZE)

Malignant Melanoma

Germany, Italy
4SC AG
Merck KGaA, Darmstadt, Germany

Withdrawn

Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1)

Merkel Cell Carcinoma
Shenzhen Geno-Immune Medical Institute

Unknown

A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies

B-cell Malignancies

China
Shenzhen Geno-Immune Medical Institute

Unknown

Combination CAR-T Cell Therapy Targeting Hematological Malignancies

B-cell Malignancies

China
Shenzhen Geno-Immune Medical Institute

Unknown

Intervention of Bladder Cancer by CAR-T

Bladder Cancer | Urothelial Carcinoma Bladder

China
Royal Marsden NHS Foundation Trust
Merck KGaA, Darmstadt, Germany; 4SC AG

Unknown

Epigenetic Modulation of the immunE Response in GastrointEstinal Cancers (EMERGE) (EMERGE)

Cancer | GI Cancer

United Kingdom
Shenzhen Geno-Immune Medical Institute

Unknown

Study on GD2 Positive Solid Tumors by 4SCAR-GD2

Solid Tumor

China
The First People's Hospital of Yunnan
Shenzhen Geno-Immune Medical Institute

Unknown

A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia

B Acute Lymphoblastic Leukemia

China
4SC AG

Completed

Open Label, Dose Escalation Trial of Oral Eg5 Kinesin-spindle Inhibitor 4SC-205 in Patients With Advanced Malignancies (AEGIS)

Malignant Lymphomas | Advanced and Incurable Solid Tumors

Germany
4SC AG

Completed

4SC-201 (Resminostat) in Advanced Colorectal Carcinoma (SHORE)

Advanced Colorectal Carcinoma

Germany
4SC AG

Completed

Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS)

Advanced Hematologic Malignancies

Germany
Peking University
University of Florida

Unknown

CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)

Lymphomas

China, United States
Peking University
University of Florida

Unknown

Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas (4SCAR19273)

B-cell Lymphomas

China
4SC AG

Completed

Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma (SAPHIRE)

Hodgkin's Lymphoma

Poland, Czech Republic, Romania
4SC AG

Completed

4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma (Shelter)

Hepatocellular Carcinoma

Germany, Italy
4SC AG

Completed

SC12267 (4SC-101) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (COMPONENT)

Rheumatoid Arthritis

Bulgaria, Czech Republic, Poland, Romania
4SC AG

Completed

SC12267 (4SC-101) for Treatment of Patients With Inflammatory Bowel Disease (ENTRANCE)

Inflammatory Bowel Disease (IBD)

Germany, Bulgaria, Romania
4SC AG

Completed

Single Dose Study With 4SC-203 in Healthy Volunteers

Acute Myeloid Leukemia

Germany

Search clinical trials for: 4SC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations